Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918047 · ClinicalTrials.gov registry record · Phase 1
Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
A Phase 1 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00918047 is a Phase 1 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT00918047, a Phase 1 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.
Interventions
- DRUG SPN-804O
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918047
The ClinicalTrials.gov registry entry for NCT00918047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPN-804O is the first listed.
NCT00918047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00918047 about?
NCT00918047 is a clinical study titled "Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients". Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.
What is the current status of trial NCT00918047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00918047?
The interventions under investigation include: SPN-804O (DRUG).
Who is sponsoring clinical trial NCT00918047?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.